Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012
PITTSBURGH, March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2012, as filed with the U.S. Securities and Exchange Commission on Feb. 28, 2013, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724.514.1813.
This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com.
SOURCE Mylan Inc.
More by this Source
Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer
Dec 18, 2013, 09:40 ET
Mylan Announces Settlement Agreement for First-to-File Generic Version of TARGRETIN®
Dec 17, 2013, 14:31 ET
Mylan Launches Cabergoline Tablets
Dec 05, 2013, 07:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.